NHS England has published clinical guidance for the use of 'Flash Glucose Monitors' for people with type 1 diabetes mellitus (T1DM). The guideline highlights funding arrangements for local health groups and outlines the qualification criteria for receiving the device.
The technology is expected to deliver better outcomes and benefits to individuals with T1DM including:
- Easier identification of rise or drop in glucose levels.
- More confidence for patients to manage their own condition.
- Significant reduction in the number of finger-prick checks.
Starting April 2019, flash glucose monitoring will be available for 1 out of 5 individuals with T1DM in England. The qualification criteria are as follows:
- T1DM requiring intensive monitoring (>8 times/day) as observed over the past 3 months.
- Diabetes associated with cystic fibrosis requiring insulin.
- T1DM in pregnant women for 12 months in total.
- Inability of disabled individuals with T1DM to self-monitor blood glucose.
- 6-month trial of Libre with appropriate support in individuals with T1DM warranted by occupational or psychosocial circumstances.
The devices will be available to patients from their local GP or diabetes team on prescription. The local groups will receive reimbursement from NHS England for the costs of the devices.
Dr Partha Kar, Associate National Clinical Director of Diabetes, said: "The guidance confirms the NHS’ commitment in improving the care of those with type 1 diabetes and signals an end to the variation in availability to the life-changing technology."